DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Imara’s IMR-687 for SCD Receives FDA Rare Pediatric Disease Designation
The U.S. Food and Drug Administration (FDA) granted rare pediatric disease designation to IMR-687, Imara’s drug candidate for the treatment of sickle cell disease (SCD). The investigational therapy has also been granted orphan drug status by the FDA.
Rare pediatric disease designation is granted to drugs that show promise for rare and serious or life-threatening diseases in U.S. patients, primarily age 18 years or younger. The designation provides incentives to advance the development of rare disease drugs, including access to the FDA’s expedited review and approval programs.
“People living with sickle cell disease have limited treatment options for its devastating effects,” James McArthur, PhD, Imara’s president and CEO, said in a news release. “The FDA’s decision reflects its commitment to working with innovators and the patient community toward advancing safe and effective treatments for children suffering from the rare and damaging pediatric manifestations of the disease.”


Related Content
-
news & eventsCalifornia’s Stem Cell Agency Invests in Stem Cell-Based Therapies Targeting Sickle Cell Disease and CancerThe California Institute for Regenerativ...
-
education & researchGreater Number of Perceived Barriers to Hydroxyurea Associated With Poorer Health-Related Quality of Life in Youth W...Background: Despite medical benefits, ...
-
education & researchHydroxyurea in sickle cell patients: A look at the correlation with hematologic malignanciesBackground: Hydroxyurea (HU) is a chemo...
-
news & eventsChief Patient Officer SummitJuly 18-20 | Boston, Massachusetts This...
-
news & eventsSiklos (hydroxyurea) now available through ProCare Pharmacy Care’s Siklos At Home programMedunik USA announced today that...
-
videos & visualsBlood Transfusions: How, Why, and When? (Part 1)https://www.youtube.com/watch?v=KRjjp0Jw...
-
news & eventsKids With Sickle Cell Anemia are More Sedentary Than Healthy Peers, Study SuggestsChildren and adolescents with sickle cel...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by

This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.